JP2015503658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503658A5 JP2015503658A5 JP2014550287A JP2014550287A JP2015503658A5 JP 2015503658 A5 JP2015503658 A5 JP 2015503658A5 JP 2014550287 A JP2014550287 A JP 2014550287A JP 2014550287 A JP2014550287 A JP 2014550287A JP 2015503658 A5 JP2015503658 A5 JP 2015503658A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- kda
- galactose
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 7
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims 7
- UNSKAUSCLTVFGO-KCDKBNATSA-N methyl (2s,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound COC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-KCDKBNATSA-N 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 102000000802 Galectin 3 Human genes 0.000 claims 3
- 108010001517 Galectin 3 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000002158 endotoxin Substances 0.000 claims 3
- 210000001616 monocyte Anatomy 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 210000001130 astrocyte Anatomy 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 230000002363 herbicidal effect Effects 0.000 claims 1
- 239000004009 herbicide Substances 0.000 claims 1
- 229920000140 heteropolymer Polymers 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000002917 insecticide Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000006198 methoxylation reaction Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- -1 nitrogenous compound Chemical class 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161580830P | 2011-12-28 | 2011-12-28 | |
| US61/580,830 | 2011-12-28 | ||
| PCT/US2012/055311 WO2013101314A1 (en) | 2011-12-28 | 2012-09-14 | Composition of novel carbohydrate drug for treatment of human diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083834A Division JP6262386B2 (ja) | 2011-12-28 | 2017-04-20 | ヒト疾患処置用の新規糖薬剤の組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503658A JP2015503658A (ja) | 2015-02-02 |
| JP2015503658A5 true JP2015503658A5 (enExample) | 2015-11-05 |
| JP6133894B2 JP6133894B2 (ja) | 2017-05-24 |
Family
ID=48698494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550287A Active JP6133894B2 (ja) | 2011-12-28 | 2012-09-14 | ヒト疾患処置用の新規糖薬剤の組成物 |
| JP2017083834A Active JP6262386B2 (ja) | 2011-12-28 | 2017-04-20 | ヒト疾患処置用の新規糖薬剤の組成物 |
| JP2017238700A Active JP6415677B2 (ja) | 2011-12-28 | 2017-12-13 | ヒト疾患処置用の新規糖薬剤の組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083834A Active JP6262386B2 (ja) | 2011-12-28 | 2017-04-20 | ヒト疾患処置用の新規糖薬剤の組成物 |
| JP2017238700A Active JP6415677B2 (ja) | 2011-12-28 | 2017-12-13 | ヒト疾患処置用の新規糖薬剤の組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US8871925B2 (enExample) |
| EP (1) | EP2797942B1 (enExample) |
| JP (3) | JP6133894B2 (enExample) |
| KR (1) | KR101968370B1 (enExample) |
| CN (1) | CN104245717B (enExample) |
| AU (2) | AU2012363033B2 (enExample) |
| BR (1) | BR112014015940B1 (enExample) |
| CA (1) | CA2861492C (enExample) |
| DK (1) | DK2797942T3 (enExample) |
| ES (1) | ES2699386T3 (enExample) |
| IL (1) | IL233313A (enExample) |
| MX (1) | MX363923B (enExample) |
| WO (1) | WO2013101314A1 (enExample) |
| ZA (1) | ZA201505849B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| JP6185473B2 (ja) * | 2011-09-16 | 2017-08-23 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
| KR101968370B1 (ko) | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
| ES2848538T3 (es) | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| BR112015005772A2 (pt) | 2012-09-17 | 2017-08-08 | Galectin Therapeutics Inc | método para a intensificação de imunoterapias específicas no tratamento de câncer |
| JP6055928B2 (ja) | 2012-10-10 | 2016-12-27 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| GB201502668D0 (en) * | 2015-02-17 | 2015-04-01 | Glycomar Ltd And Albert Bartlett & Sons Airdrie Ltd | Method for isolation of polysaccharides |
| FR3036943A1 (fr) * | 2015-06-02 | 2016-12-09 | Echosens | Dispositif non invasif de detection de lesion hepatique |
| MX394409B (es) * | 2016-03-04 | 2025-03-24 | Galectin Sciences Llc | Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos. |
| EP3568139A4 (en) * | 2017-01-13 | 2020-10-28 | Sivanaray, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR THE PREVENTION OR TREATMENT OF LIVER AND LIPID RELATED DISEASES |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| AR113011A1 (es) | 2017-09-08 | 2020-01-15 | Evelo Biosciences Inc | Vesículas extracelulares bacterianas |
| JP2021529163A (ja) | 2018-06-29 | 2021-10-28 | グリコス バイオメディカル オーワイ | コンジュゲート |
| DE102019003442A1 (de) | 2019-05-15 | 2020-11-19 | Ilma biochem GmbH | Verwendung von niedermolekularen glykosidisch gebundenen endständigen Galactosiden und Fucosiden zur Bindung von als Galectin wirkenden Toxinen im Rahmen der Behandlung von Vergiftungen, insbesondere bei Vergiftungen mit Ricin |
| US20210100832A1 (en) * | 2019-10-02 | 2021-04-08 | Patchor Ltd. | Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof |
| WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
| EP4181910A4 (en) * | 2020-07-17 | 2024-06-05 | DSM Nutritional Products, LLC | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE |
| CN116211884B (zh) * | 2023-02-16 | 2024-05-17 | 海孵(海南自贸区)医疗科技有限责任公司 | 一种鼻腔喷雾剂及其制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2132577A (en) | 1934-08-28 | 1938-10-11 | Gen Foods Corp | Method of preparing pectin |
| US2444266A (en) | 1944-03-31 | 1948-06-29 | Us Agriculture | Pectic materials and method of preparing same |
| US2503258A (en) | 1948-01-23 | 1950-04-11 | Us Agriculture | Neutralization of pectinic acids with sodium bicarbonate |
| US4016351A (en) | 1976-02-04 | 1977-04-05 | Eschinasi Emile H | Pectic substances with varying methoxyl content and process therefor |
| US4268533A (en) | 1979-11-21 | 1981-05-19 | General Foods Corporation | Quick-set low methoxyl pectin composition |
| EP0181351A4 (en) * | 1984-05-09 | 1989-06-21 | Univ Australian | METHOD FOR MODULATING IMMUNE REACTION. |
| US4686106A (en) | 1986-06-16 | 1987-08-11 | General Foods Corporation | Pectin food product |
| US5071970A (en) | 1988-11-23 | 1991-12-10 | University Of Florida | Process for producing pectin with a high-to-medium methoxyl content from beet pulp |
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| US7491708B1 (en) | 1993-03-01 | 2009-02-17 | David Platt | Modified pectin |
| JP3360899B2 (ja) | 1993-10-08 | 2003-01-07 | 日本医薬品工業株式会社 | 癌予防・治療剤 |
| US5498702A (en) | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5681923A (en) | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
| US6632797B2 (en) | 1996-06-24 | 2003-10-14 | Matti Siren | Method of treating angiogenesis |
| KR100252194B1 (ko) | 1997-10-10 | 2000-04-15 | 박호군 | 참당귀에서분리한신규한펙틴질다당류와그분리정제방법및그의면역증강제로서의용도 |
| US7022683B1 (en) * | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
| US5929051A (en) * | 1998-05-13 | 1999-07-27 | Carrington Laboratories, Inc. | Aloe pectins |
| US6500807B1 (en) | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20030004132A1 (en) | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
| US20040121981A1 (en) | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| KR100594353B1 (ko) | 2002-05-28 | 2006-07-03 | 주식회사 엠디바이오알파 | 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물 |
| JP2004107295A (ja) * | 2002-09-20 | 2004-04-08 | National Agriculture & Bio-Oriented Research Organization | ヒスタミン遊離抑制剤 |
| AU2004229399B2 (en) * | 2003-04-07 | 2010-08-05 | Prospect Therapeutics, Inc. | Composition and uses of galectin antagonists |
| US20040223971A1 (en) | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| US20050008572A1 (en) | 2003-04-29 | 2005-01-13 | Ales Prokop | Nanoparticular tumor targeting and therapy |
| US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| CA2582428A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| ITFI20040174A1 (it) * | 2004-08-03 | 2004-11-03 | Protera S R L | Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| KR101074158B1 (ko) | 2008-04-07 | 2011-10-17 | 재단법인 한국원자력의학원 | 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물 |
| US9646327B2 (en) | 2011-08-09 | 2017-05-09 | Yahoo! Inc. | Disaggregation to isolate users for ad targeting |
| JP6185473B2 (ja) | 2011-09-16 | 2017-08-23 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
| SG11201401330YA (en) * | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| KR101968370B1 (ko) | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
| ES2848538T3 (es) | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| BR112015005772A2 (pt) | 2012-09-17 | 2017-08-08 | Galectin Therapeutics Inc | método para a intensificação de imunoterapias específicas no tratamento de câncer |
| JP6055928B2 (ja) | 2012-10-10 | 2016-12-27 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
-
2012
- 2012-09-14 KR KR1020147020995A patent/KR101968370B1/ko active Active
- 2012-09-14 EP EP12863426.8A patent/EP2797942B1/en active Active
- 2012-09-14 CN CN201280068334.1A patent/CN104245717B/zh active Active
- 2012-09-14 CA CA2861492A patent/CA2861492C/en active Active
- 2012-09-14 ES ES12863426T patent/ES2699386T3/es active Active
- 2012-09-14 MX MX2014007934A patent/MX363923B/es active IP Right Grant
- 2012-09-14 JP JP2014550287A patent/JP6133894B2/ja active Active
- 2012-09-14 AU AU2012363033A patent/AU2012363033B2/en active Active
- 2012-09-14 DK DK12863426.8T patent/DK2797942T3/en active
- 2012-09-14 US US13/573,442 patent/US8871925B2/en active Active
- 2012-09-14 WO PCT/US2012/055311 patent/WO2013101314A1/en not_active Ceased
- 2012-09-14 BR BR112014015940-8A patent/BR112014015940B1/pt active IP Right Grant
-
2014
- 2014-06-23 IL IL233313A patent/IL233313A/en active IP Right Grant
- 2014-08-11 US US14/456,644 patent/US8962824B2/en active Active
- 2014-12-18 US US14/575,062 patent/US9649327B2/en active Active
-
2015
- 2015-08-14 ZA ZA2015/05849A patent/ZA201505849B/en unknown
-
2016
- 2016-09-01 AU AU2016222423A patent/AU2016222423B2/en active Active
-
2017
- 2017-04-04 US US15/478,599 patent/US9974802B2/en active Active
- 2017-04-20 JP JP2017083834A patent/JP6262386B2/ja active Active
- 2017-12-13 JP JP2017238700A patent/JP6415677B2/ja active Active
-
2018
- 2018-05-08 US US15/973,716 patent/US10420793B2/en active Active
-
2019
- 2019-07-30 US US16/525,972 patent/US10799525B2/en active Active
-
2020
- 2020-09-28 US US17/034,059 patent/US11413303B2/en active Active
-
2022
- 2022-06-29 US US17/852,453 patent/US20230000898A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503658A5 (enExample) | ||
| WO2009033756A3 (en) | Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent | |
| WO2009033799A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033667A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009039990A3 (en) | Use of icam peptide as a therapeutic agent | |
| WO2009046847A3 (en) | Use of peptide ll-37 as a therapeutic agent | |
| WO2009043463A3 (en) | Use of gluten exorphin c : as a therapeutic agent | |
| WO2009043506A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040036A3 (en) | Use of a galanin peptide as a therapeutic agent | |
| WO2009040028A3 (en) | Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis | |
| WO2009040029A3 (en) | Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis | |
| WO2009039983A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009049742A3 (en) | Use of melanotrophin-potentiating factor as a therapeutic agent | |
| WO2009046867A3 (en) | Caerulein alone or in combination with acth (3-24 ) as therapeutic agent | |
| WO2009033723A3 (en) | Use of aip2 as a therapeutic agent | |
| WO2009039986A3 (en) | Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent | |
| WO2009033746A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040032A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033754A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046860A3 (en) | Use of dago as a therapeutic agent |